Bertagna, Xavier

Diagnosis and complications of Cushing’s syndrome: a consensus statement

Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism

Pituitary Gland Disorders and TreatmentsAdrenal and Paraganglionic Tumors

Cited by 1,362

Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement

Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism

Pituitary Gland Disorders and TreatmentsAdrenal and Paraganglionic Tumors

Cited by 853

Integrated genomic characterization of adrenocortical carcinoma

Assié, G., Letouzé, E., Fassnacht, M., Jouinot, A., Luscap, W., Barreau, O., Omeiri, H., Rodriguez, S., Perlemoine, K., René-Corail, F., et al. (2014) · Nature Genetics

Adrenal and Paraganglionic TumorsChromatin Remodeling and Cancer

Cited by 732

Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy

Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 717

Mutations of β-Catenin in Adrenocortical Tumors: Activation of the Wnt Signaling Pathway Is a Frequent Event in both Benign and Malignant Adrenocortical Tumors

Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research

Adrenal and Paraganglionic TumorsWnt/β-catenin signaling in development and cancer

Cited by 474

Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors

Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsMetabolomics and Mass Spectrometry Studies

Cited by 458

Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients

Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 435

ARMC5 Mutations in Macronodular Adrenal Hyperplasia with Cushing's Syndrome

Assié, G., Libé, R., Espiard, S., Rizk-Rabin, M., Guimier, A., Luscap, W., Barreau, O., Lefèvre, L., Sibony, M., Guignat, L., et al. (2013) · New England Journal of Medicine

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 395

Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival

de Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology

Adrenal and Paraganglionic TumorsBreast Cancer Treatment Studies

Cited by 382

A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia

Horvath, A., Boikos, S., Giatzakis, C., Robinson-White, A., Groussin, L., Griffin, K. J., Stein, E., Levine, E., Delimpasi, G., Hsiao, H. P., et al. (2006) · Nature Genetics

Adrenal and Paraganglionic TumorsPhosphodiesterase function and regulation

Cited by 352

Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy

de Fraipont, F., El Atifi, M., Cherradi, N., Le Moigne, G., Defaye, G., Houlgatte, R., Bertherat, J., Bertagna, X., Plouin, P.-F., Baudin, E., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 261

Prognostic parameters of metastatic adrenocortical carcinoma

Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 236

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

Pivonello, R., Fleseriu, M., Newell-Price, J., Bertagna, X., Findling, J., Shimatsu, A., Gu, F., Auchus, R., Leelawattana, R., Lee, E. J., et al. (2020) · The Lancet Diabetes & Endocrinology

Pituitary Gland Disorders and TreatmentsAdrenal Hormones and Disorders

Cited by 222

18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients

Groussin, L., Bonardel, G., Silvéra, S., Tissier, F., Coste, J., Abiven, G., Libé, R., Bienvenu, M., Alberini, J.-L., Salenave, S., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsMedical Imaging Techniques and Applications

Cited by 215

Cloning and characterization of the human V3 pituitary vasopressin receptor

de Keyzer, Y., Auzan, C., Lenne, F., Beldjord, C., Thibonnier, M., Bertagna, X., & Clauser, E. (1994) · FEBS Letters

Neuroendocrine regulation and behaviorNeuropeptides and Animal Physiology

Cited by 209

ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences

Espiard, S., Drougat, L., Libé, R., Assié, G., Perlemoine, K., Guignat, L., Barrande, G., Brucker-Davis, F., Doullay, F., Lopez, S., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 196

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology

Pituitary Gland Disorders and TreatmentsAdrenal and Paraganglionic Tumors

Cited by 187

A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism

Tabarin, A., Achermann, J. C., Recan, D., Bex, V., Bertagna, X., Christin-Maitre, S., Ito, M., Jameson, J. L., & Bouchard, P. (2000) · Journal of Clinical Investigation

Adrenal Hormones and DisordersSexual Differentiation and Disorders

Cited by 187

Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes.

Yaneva, M., Mosnier-Pudar, H., Dugué, M.-A., Grabar, S., Fulla, Y., & Bertagna, X. (2004) · The Journal of Clinical Endocrinology & Metabolism

Pituitary Gland Disorders and TreatmentsAdrenal Hormones and Disorders

Cited by 179

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement

Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 154

Transcriptome analysis reveals that p53 and β-catenin alterations occur in a group of aggressive adrenocortical cancers

Ragazzon, B., Libé, R., Gaujoux, S., Assié, G., Fratticci, A., Launay, P., Clauser, E., Bertagna, X., Tissier, F., de Reyniès, A., et al. (2010) · Cancer Research

Adrenal and Paraganglionic TumorsChromatin Remodeling and Cancer

Cited by 152

β-Catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma

Gaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research

Adrenal and Paraganglionic TumorsChromatin Remodeling and Cancer

Cited by 146

Wnt/β-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic β-catenin gene mutations in the progression of adrenocortical tumors

Gaujoux, S., Tissier, F., Groussin, L., Libé, R., Ragazzon, B., Launay, P., Audebourg, A., Dousset, B., Bertagna, X., & Bertherat, J. (2008) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsChromatin Remodeling and Cancer

Cited by 142

Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors

Bonnet, S., Gaujoux, S., Launay, P., Baudry, C., Chokri, I., Ragazzon, B., Libé, R., René-Corail, F., Audebourg, A., Vacher-Lavenu, M.-C., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 133